AGTC Genomics

09/09/2026

𝗙𝗿𝗼𝗺 𝗜𝗺𝗺𝘂𝗻𝗼𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 — 𝗪𝗲𝗹𝗰𝗼𝗺𝗶𝗻𝗴 𝗢𝘂𝗿 𝗡𝗲𝘄 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁

We're pleased to welcome Mr. Foong Zhen Wei to AGTC Genomics as our new Applications Specialist.

Zhen Wei holds a BSc (Hons) in Biomedicine and a Master's Degree in Immunobiology (by research) from Newcastle University, UK, graduating in 2025.

In his role, he supports client engagement and the adoption of genomic solutions across the healthcare, research and industry sectors. Working closely with our scientific and commercial teams, he helps translate complex genomic technologies into practical applications — strengthening client understanding, supporting solution uptake, and contributing to our continued growth.

🤝 Client Engagement | 🧬 Genomic Solutions | 💻 Practical Applications | 📈 Business Growth

We're excited to have you on board, Zhen Wei, and look forward to the impact we'll create together. Welcome aboard! 👏

Innovating Genomics, Improving Lives.

08/09/2026

🩸 𝗔 𝗦𝗶𝗺𝗽𝗹𝗲 𝗕𝗹𝗼𝗼𝗱 𝗧𝗲𝘀𝘁. 𝗔𝗻𝘀𝘄𝗲𝗿𝘀 𝗧𝗵𝗮𝘁 𝗠𝗮𝘁𝘁𝗲𝗿.

Liquid biopsy is changing how we understand cancer.

With LiquidDx™, circulating tumour DNA (ctDNA) can be analyzed from a blood sample to uncover genomic information that may help clinicians detect mutations, monitor treatment response, track disease progression and guide personalized therapy.

More information. Less invasive sampling. Better-informed decisions.

08/09/2026

🎯 𝗙𝗿𝗼𝗺 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗱𝗮𝘁𝗮 𝘁𝗼 𝗮𝗰𝘁𝗶𝗼𝗻𝗮𝗯𝗹𝗲 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗮𝗿𝗲.

Every cancer is different. Understanding its genomic profile can help clinicians identify more personalized treatment options.

OncoDx™ provides comprehensive genomic profiling across up to 523 genes, helping connect patients with relevant targeted therapies, immunotherapies and clinical trials.

Comprehensive insights. Personalized therapies. Better outcomes.

07/09/2026

🧬 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁𝘀 𝗮𝘁 𝗔𝗚𝗧𝗖 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗲𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗧𝗲𝘀𝘁 𝗕𝗲𝗹𝗼𝘄 𝗥𝗠𝟭,𝟬𝟬𝟬

A major step forward for affordable precision oncology in Malaysia.

Revealed at NCCM 2026, the new cancer-type-specific targeted NGS test designed to detect clinically actionable mutations and gene fusions — at a price of below RM1,000.

Developed and performed locally at AGTC Genomics’ ISO 15189- and CAP-accredited laboratory, the test aims to help more patients access genomic information that can guide targeted treatment decisions earlier.

Making precision oncology more affordable, accessible and relevant to Malaysian cancer care.

https://www.agtcgenomics.com/post/scientists-at-agtc-genomics-developed-a-new-cancer-type-specific-targeted-genomic-tests-below-rm1-00

New Malaysian-developed NGS test aims to make precision oncology more affordable and accessible, enabling more patients to be matched to the right targeted treatment earlierPetaling Jaya, Malaysia, 5 September 2026 — AGTC Genomics, a Malaysian precision medicine and genomics company, has launched ...

04/09/2026

𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 𝟮𝟬𝟮𝟲 🧬

AGTC Genomics is pleased to be part of the National Cancer Congress Malaysia 2026 (NCCM), an important platform bringing together the cancer care community to exchange knowledge, strengthen collaboration, and advance better outcomes for patients.

Organised with the support of the National Cancer Society Malaysia (NCSM), NCCM provides a valuable forum for clinicians, researchers, healthcare professionals, patient advocates, policymakers, and industry partners to discuss the latest developments in cancer prevention, diagnosis, treatment, and survivorship.

As part of the programme, Professor Chee-Onn Leong will deliver a plenary presentation on “Genomic Landscape of Common Cancers in Malaysia”, highlighting how local genomic data can support more relevant, accessible, and effective precision oncology strategies.

📍 Sunway University, Kuala Lumpur
📅 4–6 September 2026

We look forward to connecting with the wider cancer community and contributing to the shared mission of improving cancer care in Malaysia.

Please join us at NCCM 2026.

03/09/2026

🎯 𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗴𝗲𝗻𝗼𝗺𝗶𝗰𝘀 𝗶𝗻𝘁𝗼 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗮𝗰𝘁𝗶𝗼𝗻.

From biopsy to sequencing, data analysis, clinical interpretation and reporting, OncoDx™ is designed to make comprehensive genomic profiling clinically actionable.

Backed by CAP-accredited laboratory quality and evidence-based interpretation, OncoDx™ helps clinicians move from genomic complexity toward more informed treatment decisions.

Advancing health. Transforming lives.

03/09/2026

🧬 𝗪𝗲’𝗿𝗲 𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘅𝘁 𝗣𝗵𝗗 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿!

IMU University and AGTC Genomics are opening a joint PhD studentship focused on:

𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗡𝗲𝘅𝘁-𝗚𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗳𝗼𝗿 𝗥𝗮𝗽𝗶𝗱 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝘂𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻

Led by Professor Dr. James Koh, Deputy Dean of IMU University and Infectious Disease Specialist, this project brings together genomics, molecular diagnostics, microbiology and clinical medicine to advance faster and more effective infectious disease detection.

We welcome candidates with:
• A relevant Master’s Degree, or
• First-Class Honours Bachelor’s Degree (CGPA ≥3.67) via the Direct Entry Pathway.

If you are passionate about genomics, infectious diseases and translational diagnostics, we would love to hear from you.

📢 Applications are now open.
https://www.agtcgenomics.com/career

02/09/2026

𝗙𝗿𝗼𝗺 𝗖𝗮𝗻𝗰𝗲𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘁𝗼 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗚𝗲𝗻𝗼𝗺𝗶𝗰𝘀 — 𝗪𝗲𝗹𝗰𝗼𝗺𝗶𝗻𝗴 𝗢𝘂𝗿 𝗡𝗲𝘄 𝗦𝗲𝗻𝗶𝗼𝗿 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁

We're delighted to welcome Ms. Jze Xi Teoh to AGTC Genomics as our new Senior Scientist.

Jze Xi holds a Master of Research in Cancer and a Bachelor of Biomedical Sciences (Hons) from Newcastle University, UK, with research experience in cancer biology and genomics — particularly in cancer cell culture and molecular techniques.

In her role, she supports our end-to-end laboratory operations, next-generation sequencing workflows, quality control and continuous workflow improvement — the behind-the-scenes rigour that ensures every result we deliver is reliable, reproducible and clinically dependable.

🧬 Cancer Biology & Genomics | 🧪 Molecular Techniques | 🔬 Next-Generation Sequencing | 🛡️ Quality & Reliability

We're excited to have you on board, Jze Xi, and look forward to the impact we'll create together. Welcome aboard! 👏

Innovating Genomics, Improving Lives.

02/09/2026

❤️ 𝗖𝗮𝗿𝗱𝗶𝗼𝗹𝗼𝗴𝘆 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗧𝗲𝘀𝘁: 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗚𝗲𝗻𝗲𝘁𝗶𝗰 𝗖𝗮𝘂𝘀𝗲 𝗕𝗲𝗵𝗶𝗻𝗱 𝗜𝗻𝗵𝗲𝗿𝗶𝘁𝗲𝗱 𝗛𝗲𝗮𝗿𝘁 𝗖𝗼𝗻𝗱𝗶𝘁𝗶𝗼𝗻𝘀

Many cardiovascular disorders can have an underlying genetic cause. Identifying that cause can support more confident diagnosis, risk assessment, patient management and cascade testing for at-risk family members.

AGTC Genomics introduces our Cardiology Genetic Test, a comprehensive Next-Generation Sequencing (NGS) service covering inherited cardiovascular conditions including cardiomyopathies, arrhythmias, aortopathies, lipid disorders and congenital heart disease.

🧬 510 genes on one comprehensive panel
🎯 23 phenotype-focused sub-panels
⏱️ 7–14 day turnaround time

Key areas covered include:

• 𝗖𝗮𝗿𝗱𝗶𝗼𝗺𝘆𝗼𝗽𝗮𝘁𝗵𝗶𝗲𝘀 – hypertrophic, LV non-compaction, arrhythmogenic cardiomyopathy and more
• 𝗔𝗿𝗿𝗵𝘆𝘁𝗵𝗺𝗶𝗮𝘀 & 𝗰𝗵𝗮𝗻𝗻𝗲𝗹𝗼𝗽𝗮𝘁𝗵𝗶𝗲𝘀 – Long QT, Short QT, Brugada syndrome and CPVT
• 𝗔𝗼𝗿𝘁𝗼𝗽𝗮𝘁𝗵𝗶𝗲𝘀 & 𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗶𝘀𝘀𝘂𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 – including Marfan, Loeys-Dietz and Ehlers-Danlos syndromes
• 𝗟𝗶𝗽𝗶𝗱 & 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝗰 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 – including familial hypercholesterolaemia
• 𝗖𝗼𝗻𝗴𝗲𝗻𝗶𝘁𝗮𝗹 & 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗵𝗲𝗮𝗿𝘁 𝗱𝗶𝘀𝗲𝗮𝘀𝗲
• 𝗩𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 – including pulmonary arterial hypertension
• 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻g

When should genetic testing be considered?

🔹 Cardiomyopathy diagnosed at any age
🔹 Unexplained sudden cardiac death or aborted cardiac arrest in the family
🔹 Long QT or Brugada ECG pattern, or unexplained syncope
🔹 Aortic aneurysm or dissection at a young age
🔹 Marked hypercholesterolaemia or premature coronary disease
🔹 Familial or syndromic congenital heart disease

A confirmed molecular diagnosis can also provide a clear starting point for targeted cascade testing of first-degree relatives, helping identify family members who may benefit from appropriate clinical evaluation.

Why AGTC Genomics?

✅ CAP-accredited NGS laboratory
✅ Malaysian laboratory with local logistics and regional support
✅ Comprehensive or phenotype-focused testing from the same NGS backbone
✅ Pre- and post-test consultation
✅ Genetic counselling support
✅ Clinician-ready reports

One sample. One comprehensive platform. More precise answers for inherited cardiovascular disease.

📩 [email protected]
📞 +6012 520 7981
🌐 agtcgenomics.com

02/09/2026

🧬 𝗟𝗶𝗾𝘂𝗶𝗱𝗗𝘅: 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗳𝗿𝗼𝗺 𝗮 𝗦𝗶𝗺𝗽𝗹𝗲 𝗕𝗹𝗼𝗼𝗱 𝗗𝗿𝗮𝘄

Cancer evolves—and treatment decisions may need to evolve with it.

LiquidDx™ ctDNA Liquid Biopsy analyzes circulating tumour DNA in blood to provide genomic insights that can help clinicians:

🔹 Detect actionable mutations
🔹 Monitor treatment response
🔹 Guide personalized therapy
🔹 Track disease progression

Non-invasive. Precise. Comprehensive. Timely.

Advanced genomic testing to support better-informed cancer care.